Showing 641 - 660 results of 1,890 for search '"Type 2 diabetes"', query time: 0.16s Refine Results
  1. 641
  2. 642

    Study the effect of urokinase-type plasminogen activator (UPA) and some biochemical parameters in Iraqi hemodialysis patients with type 2 diabetes by Fatima Ali Essa Al-Sudani, Nawal Mohammed Jawad Al-Shammaa

    Published 2024-01-01
    “…Abstract The most common cause of end-stage renal disease (ESRD) and leading ultimately to hemodialysis (HD) is type 2 diabetes mellitus (T2DM). The current study aims to assess the role of serum urokinase plasminogen activator (UPA) levels among Iraqi hemodialysis patients with ESRD with type 2 diabetes. …”
    Get full text
    Article
  3. 643

    Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes by Mazhar Hussain, Asim Elahi, Abid Hussain, Javed Iqbal, Lubna Akhtar, Abdul Majid

    Published 2021-01-01
    “…SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.…”
    Get full text
    Article
  4. 644
  5. 645
  6. 646

    Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients by Lingshu Wang, Jun Song, Chuan Wang, Peng Lin, Kai Liang, Yu Sun, Tianyi He, Wenjuan Li, Ruxing Zhao, Jun Qin, Yiran Lu, Jinbo Liu, Fuqiang Liu, Xinguo Hou, Li Chen

    Published 2016-01-01
    “…The present study aims to demonstrate the associations of circulating betatrophin and irisin levels with β-cell function, assessed by the area under the curve (AUC) of C-peptide, and the possible correlation between these two hormones in previously diagnosed type 2 diabetes mellitus (T2DM) patients. In total, 20 age-, sex-, and body mass index- (BMI-) matched normal glucose tolerance (NGT) subjects and 120 previously diagnosed T2DM patients were included in this study. …”
    Get full text
    Article
  7. 647

    Frameshift variation in the HMG-CoA reductase gene and unresponsiveness to cholesterol-lowering drugs in type 2 diabetes mellitus patients by Esmat Khaleqsefat, Khder Hussein Rasul, Ramiar Kamal Kheder, Sonia Baban, Jamil Baban

    Published 2025-01-01
    “…Abstract Dyslipidemia, an imbalance in blood lipid levels, is a frequent complication of type 2 diabetes mellitus (DM2) and heightens the risk of cardiovascular diseases (CVDs). …”
    Get full text
    Article
  8. 648
  9. 649
  10. 650

    Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study by Lingli Zhou, Xiaoling Cai, Yingying Luo, Fang Zhang, Linong Ji

    Published 2019-01-01
    “…Identifying factors that may impact vildagliptin’s efficacy could contribute to individualized treatment for patients with type 2 diabetes. In the current study, we aimed to assess the correlation between patient baseline triglyceride (TG) and efficacy of vildagliptin in Chinese patients with type 2 diabetes in a post hoc analysis of the VISION study. …”
    Get full text
    Article
  11. 651

    Liver Biomarkers and Lipid Profiles in Mexican and Mexican-American 10- to 14-Year-Old Adolescents at Risk for Type 2 Diabetes by Ana Cecilia Fernández-Gaxiola, Roxana Valdés-Ramos, Kimberly Fulda, Ana Laura Guadarrama López, Beatriz E. Martínez-Carrillo, Susan F. Franks, Shane Fernando

    Published 2017-01-01
    “…Liver enzymes alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) are markers for type 2 diabetes mellitus (T2DM); alkaline phosphatase is a marker of liver disease. …”
    Get full text
    Article
  12. 652

    The Referral System between Primary and Secondary Health Care in Saudi Arabia for Patients with Type 2 Diabetes: A Systematic Review by Mohammed Senitan, Ali Hassan Alhaiti, James Gillespie, Badar Faiz Alotaibi, George Binh Lenon

    Published 2017-01-01
    “…A single reviewer employed a systematic approach to searching the literature databases with regard to the question: what are the attributes of referral systems in Saudi Arabia for patients with type 2 diabetes (T2D)? The results were analysed in order to provide recommendations to improve the Saudi health system. …”
    Get full text
    Article
  13. 653

    Impact of Pre-existing Type 2 Diabetes Mellitus and Cardiovascular Disease on Healthcare Resource Utilization and Costs in Patients With COVID-19 by Chi Nguyen, Christopher L. Crowe, Effie Kuti, Bonnie Donato, Rachel Djaraher, Leo Seman, Nancy Graeter, Thomas P. Power, Rinku Mehra, Vincent J. Willey

    Published 2024-04-01
    “…**Background:** The economic burden associated with type 2 diabetes mellitus (T2DM) and concurrent cardiovascular disease (CVD) among patients with COVID-19 is unclear. …”
    Get full text
    Article
  14. 654

    The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class? by Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis

    Published 2015-01-01
    “…Incretin-based therapies, the most recent therapeutic options for type 2 diabetes mellitus (T2DM) management, can modify various elements of the disease, including hypersecretion of glucagon, abnormal gastric emptying, postprandial hyperglycaemia, and, possibly, pancreatic β cell dysfunction. …”
    Get full text
    Article
  15. 655

    Pleiotropic Effects of a KCNQ1 Variant on Lipid Profiles and Type 2 Diabetes: A Family-Based Study in China by Xiaowen Wang, Junhui Wu, Yao Wu, Mengying Wang, Zijing Wang, Tao Wu, Dafang Chen, Xun Tang, Xueying Qin, Yiqun Wu, Yonghua Hu

    Published 2020-01-01
    “…The genetic variant rs2237895, located in the Potassium Voltage-Gated Channel Subfamily Q Member 1 (KCNQ1) gene, has been replicated to be associated with type 2 diabetes mellitus (T2DM) susceptibility, but the relationship with lipids is conflicting. …”
    Get full text
    Article
  16. 656
  17. 657

    Early Postoperative Outcomes and Medication Cost Savings after Laparoscopic Sleeve Gastrectomy in Morbidly Obese Patients with Type 2 Diabetes by Bethany J. Slater, Nina Bellatorre, Dan Eisenberg

    Published 2011-01-01
    “…Morbidly obese patients with type 2 diabetes who underwent LSG were included in the study. …”
    Get full text
    Article
  18. 658

    Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus by Bindu Chamarthi, J. Michael Gaziano, Lawrence Blonde, Aaron Vinik, Richard E. Scranton, Michael Ezrokhi, Dean Rutty, Anthony H. Cincotta

    Published 2015-01-01
    “…Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). …”
    Get full text
    Article
  19. 659

    Sex Differences in the Effect of Type 2 Diabetes on Major Cardiovascular Diseases: Results from a Population-Based Study in Italy by Paola Ballotari, Francesco Venturelli, Marina Greci, Paolo Giorgi Rossi, Valeria Manicardi

    Published 2017-01-01
    “…The aim of the study is to assess sex difference in association between type 2 diabetes and incidence of major cardiovascular events, that is, myocardial infarction, stroke, and heart failure, using information retrieved by diabetes register. …”
    Get full text
    Article
  20. 660